Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Bol, Kalijn F ^a,b   Aarntzen, Erik H J G ^a,b   in ’t Hout, Florentien E M ^a,b   Schreibelt, Gerty ^a   Creemers, Jeroen H A ^a   Lesterhuis, W Joost ^a,c   Gerritsen, Winald R ^b   Grunhagen, Dirk J ^d   Verhoef, Cornelis ^d   Punt, Cornelis J A ^e   Bonenkamp, Johannes J ^b   de Wilt, Johannes H W ^b   Figdor, Carl G ^a   de Vries, I Jolanda M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant therapy; Dendritic cell; Immunotherapy; Melanoma; Vaccination

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN GP 100; HLA A ANTIGEN; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ADJUVANT DENDRITIC CELL VACCINATION; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; CYTOTOXICITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; METASTASIS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SKIN TEST; THORAX RADIOGRAPHY; TOXICITY TESTING;

EID: 84954456996     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1057673     Document Type: Article

References (45)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150:179-85; PMID:14996086; http://dx. doi. org/10. 1111/j. 1365-2133. 2004. 05708. x
2. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3-9; PMID:19095149; http:// dx. doi. org/10. 1016/j. clindermatol. 2008. 09. 001
3. Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009; 115:5836-44; PMID:19701906; http:// dx. doi. org/10. 1002/cncr. 24627
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx. doi. org/ 10. 1200/JCO. 2009. 23. 4799
5. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-34; PMID:11504744
6. van Akkooi AC, Bouwhuis MG, de Wilt JH, Kliffen M, Schmitz PI, Eggermont AM. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg 2007; 94:1293-9; PMID:17702089; http://dx. doi. org/10. 1002/bjs. 5814
7. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48; PMID:11504745
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx. doi. org/10. 1056/NEJMoa1103782
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx. doi. org/10. 1056/NEJMoa1003466
10. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx. doi. org/10. 1056/ NEJMoa1104621
11. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9; PMID:25399551; http://dx. doi. org/10. 1056/NEJMoa1412690
12. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13:589-97; PMID:22575589; http://dx. doi. org/ 10. 1016/S1470-2045(12)70138-9
13. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 2009; 19:275-82; PMID:19633580; http://dx. doi. org/10. 1097/ CMR. 0b013e32832eabd5
14. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117-26; PMID:18620949; http://dx. doi. org/10. 1016/S0140-6736(08)61033-8
15. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for highrisk melanoma provide a worthwhile benefit? A metaanalysis of the randomised trials. Cancer Treat Rev 2003; 29:241-52; PMID:12927565; http://dx. doi. org/ 10. 1016/S0305-7372(03)00074-4
16. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522-30; PMID:25840693; http://dx. doi. org/ 10. 1016/S1470-2045(15)70122-1
17. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106:1431-42; PMID:16511841; http://dx. doi. org/10. 1002/cncr. 21760
18. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill PG, Coventry BJ, McMullen A, Dillon H et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002; 20:4181-90; PMID:12377961; http://dx. doi. org/10. 1200/JCO. 2002. 12. 094
19. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27; PMID:21631324; http://dx. doi. org/10. 1056/NEJMoa1012863
20. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster J, Xu Y, Nooyen P, McClanahan T et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997; 387:713-7; PMID:9192897; http://dx. doi. org/ 10. 1038/42716
21. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx. doi. org/10. 1038/32588
22. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate antitumor immune responses in vivo. Nat Med 1999; 5:405-11; PMID:10202929; http://dx. doi. org/ 10. 1038/7403
23. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx. doi. org/10. 1038/ nature06175
24. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:15122249; http://dx. doi. org/ 10. 1038/nm1039
25. Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008; 66:118-34; PMID:18262431; http://dx. doi. org/10. 1016/j. critrevonc. 2007. 12. 007
26. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM et al. Multivariate analysis of prognostic factors among 2, 313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28:2452-9; PMID:20368546; http://dx. doi. org/10. 1200/ JCO. 2009. 27. 1627
27. Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, van Rossum MM, Adema GJ, Figdor CG, Punt CJ, de Vries IJ. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell based vaccination in metastatic melanoma. Cancer Res 2012: 72:6102-10; PMID:23010076; http://dx. doi. org/ 10. 1158/0008-5472. CAN-12-2479
28. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23:5779-87; PMID:16110035; http://dx. doi. org/10. 1200/ JCO. 2005. 06. 478
29. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13:5256-61; PMID:17875753; http://dx. doi. org/10. 1158/1078-0432. CCR-07-0892
30. van Akkooi AC, Bouwhuis MG, van Geel AN, Hoedemaker R, Verhoef C, Grunhagen DJ, Schmitz PI, Eggermont AM, de Wilt JH. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007; 33:102-8; PMID:17161577; http://dx. doi. org/10. 1016/j. ejso. 2006. 10. 032
31. Wevers KP, Bastiaannet E, Poos HP, van Ginkel RJ, Plukker JT, Hoekstra HJ. Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites? Ann Surg Oncol 2012:19:3913-8; PMID:22588472; http://dx. doi. org/10. 1245/ s10434-012-2401-8
32. Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72:233-40; PMID:7058834; http://dx. doi. org/ 10. 1016/0002-9343(82)90815-4
33. Morton DL, Hsueh EC, Essner R, Foshag LJ, O'Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002; 236:438-48; discussion 48-9; PMID:12368672; http:// dx. doi. org/10. 1097/00000658-200210000-00006
34. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Meeting Abstracts 2014; 32:LBA9008.
35. Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG et al. Wildtype and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 2011; 60:249-60; PMID:21069321; http://dx. doi. org/10. 1007/s00262-010-0942-x
36. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17:5725-35; PMID:21771874; http://dx. doi. org/10. 1158/1078-0432. CCR-11-1261
37. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx. doi. org/10. 1158/ 0008-5472. CAN-12-1127
38. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx. doi. org/10. 1158/1078-0432. CCR-11-3368
39. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, Schuler-Thurner B. Largescale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 2002; 268:131-40; PMID:12215381; http:// dx. doi. org/10. 1016/S0022-1759(02)00189-8
40. de Vries IJ, Adema GJ, Punt CJ, Figdor CG. Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med 2005; 109:113-26; PMID:15585917
41. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996; 183:1965-71; PMID:8642306; http://dx. doi. org/10. 1084/jem. 183. 5. 1965
42. Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C, Zeuthen J, Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998; 47:32-8; PMID:9755876; http://dx. doi. org/10. 1007/ s002620050501
43. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9:5091-100; PMID:14613986
44. Bakker AB, van der Burg SH, Huijbens RJ, Drijfhout JW, Melief CJ, Adema GJ, Figdor CG. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int J Cancer 1997; 70:302-9; PMID:9033632; http://dx. doi. org/10. 1002/(SICI) 1097-0215(19970127)70:3%3c302::AIDIJC10% 3e3. 0. CO;2-H
45. Schuurhuis DH, Lesterhuis WJ, Kramer M, Looman MG, van Hout-Kuijer M, Schreibelt G, Boullart AC, Aarntzen EH, Benitez-Ribas D, Figdor CG et al. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother 2009; 58:1109-15; PMID:19018531; http://dx. doi. org/10. 1007/ s00262-008-0626-y